BMS-986016

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986016 is one of 10 small molecule programs targeting Colon Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colon CarcinomaRecruiting

Colon CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Colon Carcinoma

#DrugCompanyPhaseTrials

Retevmo

Tarceva

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Approved

—4

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—5

Dacogen

Sun Pharmaceutical Industries, Inc.

Avastin

Celebrex

PPhiladelphia Eye Associates

Preclinical

1 8

Erbitux

IImclone

Preclinical

—9

Injectafer

AAmerican Regent, Inc.

BMS-986016

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Colon Carcinoma

NCT03026140

Clinical

Trials by Indication[1]

Relapsed or Refractory B-cell Malignancies1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02061761·106 enrolled

Glioblastoma1 trial

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT03493932·21 enrolled

Combination Therapy1 trial

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02060188·385 enrolled

Colon Carcinoma1 trial

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03026140·353 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BMS-986016. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986016 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986016. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986016

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Relapsed or Refractory B-cell Malignancies1 trial

Glioblastoma1 trial

Combination Therapy1 trial

Colon Carcinoma1 trial

References

Drug Info

Quick Facts

Related News